After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment.